On September 27, Shanghai Medicilon Inc. and InnoDrug Lab. (Hong Kong) Co., Limited officially signed a strategic cooperation agreement. The two parties plan to jointly advance 5 innovative drug IND projects over the next 3 years, focusing on unmet clinical needs in cardiovascular and cerebrovascular diseases, metabolic disorders, and inflammatory and immune conditions, accelerating the development of innovative drugs with global competitive advantages.

Professor Zhu Yizhun, Chairman of InnoDrug, and Dr. Shanhong Huang, Vice President; Dr. Chunlin Chen, Founder, Chairman & CEO of Medicilon, Dr. Jinna Cai, Director & Chief Business Officer, Professor Shuangqing Peng, Chief Scientific Officer, Dr. Maosheng Duan, President of Drug Discovery & Pharmaceutical Research Division, and Dr. Jian Ge, President of Preclinical Division, along with other core team members from both parties, attended and witnessed this significant moment.

InnoDrug’s Innovative Pipeline + Medicilon’s One-Stop Platform Building a New Ecosystem for Chronic Disease R&D

InnoDrug is an innovative enterprise at the clinical research stage, focusing on first-in-class new drug development, founded by Chair Professor Zhu Yizhun, a member of the European Academy of Sciences and Arts, National Distinguished Young Scholar, and Changjiang Scholar. The company is dedicated to breakthrough research in major chronic diseases including cardiovascular and cerebrovascular diseases, metabolic disorders, and inflammatory and immune conditions, with a pipeline of 20 clinical and preclinical innovative drugs with independent intellectual property rights. The team’s research series has been featured in groundbreaking reports by top international journals such as Science and C&EN from the American Chemical Society, demonstrating profound translational medicine research and original innovation capabilities.

Medicilon has been deeply engaged in preclinical biopharmaceutical R&D for over two decades and has become a leading one-stop preclinical biopharmaceutical R&D service platform in China, establishing a quality management system that complies with international standards. The company has built R&D service platforms in cutting-edge fields including ADC, nucleic acids, PROTAC, antibodies, peptides, vaccines, and CGT. As of the end of June 2025, Medicilon has facilitated 588 INDs approved by China’s CFDA/NMPA, US FDA, Australia’s TGA, Europe’s EMEA, and Korea’s KFDA for clinical trials, accumulating extensive experience in global regulatory submissions and compliant delivery.

This strategic cooperation stems from the high degree of mutual trust and synergistic effects accumulated through previous project collaborations between the two parties. Moving forward, both sides will deeply integrate InnoDrug’s advantages in original innovation and pipeline development with Medicilon’s extensive experience in one-stop R&D services, quality systems, and global regulatory submissions, jointly building an efficiently coordinated R&D innovation ecosystem.

Advancing 5 INDs in 3 Years Accelerating Innovative Drug Discovery for Major Chronic Diseases

According to the agreement, Medicilon will become InnoDrug’s preferred partner in preclinical R&D, providing comprehensive services covering drug discovery, pharmaceutical research, pharmacodynamic and pharmacokinetic evaluation, safety assessment, and complete IND application documentation. Both parties have clearly set “achieving 5 IND project submissions within 3 years” as a phased objective to jointly advance the preclinical development of innovative drugs.